These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37370814)

  • 1. Taxifolin Inhibits Breast Cancer Growth by Facilitating CD8+ T Cell Infiltration and Inducing a Novel Set of Genes including Potential Tumor Suppressor Genes in 1q21.3.
    Lin X; Dong Y; Gu Y; Kapoor A; Peng J; Su Y; Wei F; Wang Y; Yang C; Gill A; Neira SV; Tang D
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
    O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxifolin Inhibits the Growth of Non-Small-Cell Lung Cancer via Downregulating Genes Displaying Novel and Robust Associations with Immune Evasion Factors.
    Lin X; Dong Y; Gu Y; Wei F; Peng J; Su Y; Wang Y; Yang C; Neira SV; Kapoor A; Tang D
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
    Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
    Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.
    Katsuta E; Yan L; Opyrchal M; Kalinski P; Takabe K
    Ther Adv Med Oncol; 2021; 13():17588359211006680. PubMed ID: 33868461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    De Palma FDE; Del Monaco V; Pol JG; Kremer M; D'Argenio V; Stoll G; Montanaro D; Uszczyńska-Ratajczak B; Klein CC; Vlasova A; Botti G; D'Aiuto M; Baldi A; Guigó R; Kroemer G; Maiuri MC; Salvatore F
    Pharmacol Res; 2020 Nov; 161():105249. PubMed ID: 33068730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
    BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
    Papaioannou E; Sakellakis M; Melachrinou M; Tzoracoleftherakis E; Kalofonos H; Kourea E
    Anticancer Res; 2019 Mar; 39(3):1217-1232. PubMed ID: 30842152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
    Tang W; Xu F; Zhao M; Zhang S
    BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Oshi M; Ziazadeh D; Wu R; Chida K; Yamada A; Yamamoto S; Narui K; Yan L; Ishikawa T; Endo I; Takabe K
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis.
    Gan S; Dai H; Li R; Liu W; Ye R; Ha Y; Di X; Hu W; Zhang Z; Sun Y
    Gland Surg; 2020 Jun; 9(3):661-675. PubMed ID: 32775256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer.
    Fang Z; Song YX; Wo GQ; Zhou HL; Li L; Yang SY; Chen X; Zhang J; Tang JH
    Ann Transl Med; 2022 Dec; 10(23):1280. PubMed ID: 36618780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
    Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
    Front Immunol; 2022; 13():859581. PubMed ID: 35795662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
    Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
    Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq.
    Xu J; Qin S; Yi Y; Gao H; Liu X; Ma F; Guan M
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer.
    Wu M; Yuan K; Lyu S; Li Y
    World J Surg Oncol; 2022 Jun; 20(1):214. PubMed ID: 35751103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer.
    Liu Q; Huang S; Desautels D; McManus KJ; Murphy L; Hu P
    Comput Struct Biotechnol J; 2023; 21():2940-2949. PubMed ID: 37216014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of CYB5D2 is associated with breast cancer progression.
    Ojo D; Rodriguez D; Wei F; Bane A; Tang D
    Sci Rep; 2019 Apr; 9(1):6624. PubMed ID: 31036830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.